• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lalan Wilfong on the Struggle for Reimbursement of Novel Cancer Therapies

Video

"The cost of cancer care is rising dramatically," said Lalan Wilfong, MD, executive vice president of quality programs at Texas Oncology.

"The cost of cancer care is rising dramatically," said Lalan Wilfong, MD, executive vice president of quality programs at Texas Oncology.

What is the struggle for reimbursement for new innovative cancer therapies?Transcript:

So, cost of cancer care is rising dramatically, and the cost of new innovative cancer therapies is quite high— there are many reasons behind that– but the cost of care is quite high. It’s difficult to address that in a practice because we don’t control the cost of care. You want to provide the appropriate care for the appropriate patient at the appropriate time– that’s the mantra for taking good care of patients.

It’s a difficult question to figure out how do we address that in the care that we provide. I think pathways is one way to do that where we can look at what an appropriate, new, innovative therapy is and which patient population they should be given to. Doing innovative payment adjustments is also important so the practices aren’t discouraged from using novel therapies where they are appropriate. I think the challenge is figuring out which novel therapies are appropriate for which patients and making sure you’re utilizing them appropriately for the patients that you have.

Related Videos
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Interview screenshot with Megan Ehret, PharmD
Screenshot of an interview with Susan Wescott, RPh, MBA
Screenshot of an interview with Nadine Barrett, PhD
Female doctor in coat with stethoscope on blue background - Pixel-Shot - stock.adobe.com
Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.